The Beauty Health Company (NASDAQ:SKIN) Given Average Rating of “Reduce” by Analysts

Shares of The Beauty Health Company (NASDAQ:SKIN) have earned an average rating of “Reduce” from the twelve brokerages that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $6.50.

Several equities analysts have recently issued reports on the stock. Piper Sandler reissued an “underweight” rating and issued a $3.00 price target (up previously from $2.00) on shares of Beauty Health in a report on Wednesday, March 13th. DA Davidson reissued a “buy” rating and issued a $5.00 price target on shares of Beauty Health in a report on Friday, March 15th. TD Cowen boosted their price target on shares of Beauty Health from $2.50 to $4.00 and gave the company a “market perform” rating in a report on Wednesday, March 13th. Canaccord Genuity Group upped their target price on shares of Beauty Health from $3.00 to $4.00 and gave the stock a “hold” rating in a research note on Thursday, March 14th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $4.00 target price (up from $3.00) on shares of Beauty Health in a research note on Wednesday, March 13th.

Beauty Health Price Performance

SKIN opened at $3.06 on Friday. The company has a fifty day moving average price of $3.65 and a two-hundred day moving average price of $3.43. The company has a debt-to-equity ratio of 12.43, a quick ratio of 5.28 and a current ratio of 6.07. Beauty Health has a 52 week low of $1.35 and a 52 week high of $11.82. The firm has a market capitalization of $377.70 million, a PE ratio of -3.97 and a beta of 1.01.

Beauty Health (NASDAQ:SKIN) last announced its quarterly earnings results on Tuesday, March 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. Beauty Health had a negative net margin of 25.65% and a negative return on equity of 18.85%. The company had revenue of $96.80 million during the quarter, compared to analyst estimates of $87.22 million. During the same quarter in the previous year, the business earned $0.03 EPS. The firm’s revenue was down 1.3% on a year-over-year basis. As a group, analysts anticipate that Beauty Health will post -0.1 earnings per share for the current year.

Institutional Investors Weigh In On Beauty Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Services Advisors Inc. bought a new stake in Beauty Health during the 4th quarter worth about $31,000. Raymond James & Associates bought a new stake in Beauty Health during the 4th quarter worth about $31,000. Sherbrooke Park Advisers LLC bought a new stake in shares of Beauty Health in the 3rd quarter valued at about $90,000. Kestra Private Wealth Services LLC raised its holdings in shares of Beauty Health by 40.8% in the 3rd quarter. Kestra Private Wealth Services LLC now owns 15,887 shares of the company’s stock valued at $96,000 after purchasing an additional 4,600 shares during the period. Finally, Fox Run Management L.L.C. bought a new stake in shares of Beauty Health in the 3rd quarter valued at about $97,000. 93.26% of the stock is owned by institutional investors.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.